這是以色列的study.
CONCLUSIONS
Among patients 65 years of age or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir than among those who did not. No evidence of benefit was found in younger adults.
https://www.nejm.org/doi/full/10.1056/NEJMoa2204919